Iovance Biotherapeutics Inc reports results for the quarter ended June 30 - Earnings Summary

• Iovance Biotherapeutics Inc IOVA.OQ reported a quarterly adjusted loss of 33 cents​​ per share for the quarter ended June 30, higher than the same quarter last year, when the company reported EPS of -34 cents. The mean expectation of twelve analysts for the quarter was for a loss of 28 cents per share. Wall Street expected results to range from -34 cents to -25 cents per share.

• Revenue rose 92.7% to $59.95 million from a year ago; analysts expected $69.79 million.

• Iovance Biotherapeutics Inc's reported EPS for the quarter was a loss of 33 cents​.

• The company reported a quarterly loss of $111.66 million.

• Iovance Biotherapeutics Inc shares had risen by 50.0% this quarter and lost 65.1% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts had risen by about 1.3% in the last three months.​

• In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy," 4 "hold" and 1 "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

• Wall Street's median 12-month price target for Iovance Biotherapeutics Inc is $7.50, about 64.8% above its last closing price of $2.64

This summary was machine generated from LSEG data August 8 at 03:35 a.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)